USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
29 Nov 2022 | 03:45 PM GMT

Roadmap Execution in a Pharma-DTx Partnership

Anchored by:

Till Bauer
Global Oncology LCM Strategy Director
MSD

Participants:

Till Bauer Global Oncology LCM Strategy DirectorMSD
Till Bauer
Global Oncology LCM Strategy DirectorMSD
Francesca Wuttke Founder & CEOnen Health
Francesca Wuttke
Founder & CEOnen Health
Ameya Phadke Senior Director, Non Pharma SolutionsChiesi Group
Ameya Phadke
Senior Director, Non Pharma SolutionsChiesi Group
Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Elisabeth Tsechanski Digital Innovation HubDaiichi Sankyo Europe
Elisabeth Tsechanski
Digital Innovation HubDaiichi Sankyo Europe
Jeff Wandzura CEOKEEP Labs
Jeff Wandzura
CEOKEEP Labs
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Michael Levy Chief Executive OfficerDigital Health Institute for Transformation
Michael Levy
Chief Executive OfficerDigital Health Institute for Transformation
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Steve Peretz Healthcare Practice Lead, Digital ProductsAppnovation
Steve Peretz
Healthcare Practice Lead, Digital ProductsAppnovation
Vasyl Pyrozhyk Vice PresidentSMBC
Vasyl Pyrozhyk
Vice PresidentSMBC
Wen Dombrowski MD MBA Chief Convergence OfficerCATALAIZE
Wen Dombrowski MD MBA
Chief Convergence OfficerCATALAIZE

About this Meeting

While the number of partnerships between DTx and Pharma have grown in the past years, we haven’t seen big successes yet, and part of that could be due to bad roadmap definition and its execution. Despite the areas of agreement between the two parties and the huge potential in Pharma-DTx alliances, translating ambition into successful execution presents many challenges. 

Having a clear roadmap can ensure that both parties’ objectives are aligned, but top-notch execution is also a key to success. Join this session deeper conversation about:  

  • When DTx and Pharma reach an agreement and have a clear roadmap, what is the next step? How to guarantee from day 1, the partnership will succeed?   
  • After building and agreeing on a roadmap, what are the conflicts Pharma and DTx companies face during the partnership? How to overcome those? 
  • How can pharma build the internal operations that will support partnerships with DTx companies? Who within the pharma company needs to lead these operational changes? 
  • How can pharma companies reach parallel paths of procurement, legal, data privacy and compliance to make a partnership work?  
  • What can we learn from unsuccessful partnerships to help us execute better?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.